Skip to main content

FDA clears use of Lilly's COVID-19 antibody therapy for kids

By Reuters  
   December 06, 2021

The U.S. Food and Drug Administration on Friday authorized the use of Eli Lilly's (LLY.N) COVID-19 dual-antibody therapy in treating mild to moderate symptoms in all children, including newborns, who are at risk of severe illness.

Full story


Get the latest on healthcare leadership in your inbox.